Literature DB >> 8243852

Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

G Jerums1, T J Allen, C Tsalamandris, A Akdeniz, A Sinha, R Gilbert, M E Cooper.   

Abstract

This study has explored the temporal relationship between apoprotein(a), blood pressure and albuminuria over a mean interval of 11 years in a cohort of 107 diabetic patients of whom 26 (14 Type 2 (non-insulin-dependent), 12 Type 1 (insulin-dependent) had progressively increasing albuminuria ('progressors'). In Type 2 diabetic patients, no significant differences were noted for HbA1, blood pressure, creatinine clearance or serum lipids between progressors and non-progressors. In Type 1 diabetic patients, final systolic and diastolic blood pressures were higher in progressors compared with non-progressors and progressors showed impairment of renal function in association with a rise in blood pressure at the macroalbuminuric stage. Initial apoprotein(a) levels were similar in progressors and non-progressors of either diabetes type. Apoprotein(a) levels increased exponentially with time in 12 of 14 Type 2 progressors but only in 5 of 12 Type 1 progressors (p < 0.01). In Type 2 diabetic patients, the annual increase in apoprotein(a) levels was 9.1 +/- 2.4%, which was significantly greater than in non-progressors, 2.0 +/- 1.2% (p < 0.01) and also exceeded the rates of increase of apoprotein(a) in progressors with Type 1 diabetes, 4.0 +/- 1.4%, (p < 0.05). Apoprotein(a) levels correlated significantly with albuminuria in 8 of 14 Type 2 progressors but only in 3 of 12 Type 1 progressors (p < 0.05). The rate of increase of apoprotein(a) levels was not related to mean HbA1, creatinine or creatinine clearance levels, or to albuminuria.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243852     DOI: 10.1007/bf02374496

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  41 in total

1.  [Enzymatic determination of glucose and fructose simultaneously].

Authors:  F H SCHMIDT
Journal:  Klin Wochenschr       Date:  1961-12-01

2.  The effect of metabolic regulation on microvascular permeability to small and large molecules in short-term juvenile diabetics.

Authors:  H H Parving; I Noer; T Deckert; P E Evrin; S L Nielsen; J Lyngsoe; C E Mogensen; M Rorth; P A Svendsen; J Trap-Jensen; N A Lassen
Journal:  Diabetologia       Date:  1976-05       Impact factor: 10.122

3.  Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis.

Authors:  C Lackner; E Boerwinkle; C C Leffert; T Rahmig; H H Hobbs
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Sample size for clinical and biological research.

Authors:  L A Bach; K Sharpe
Journal:  Aust N Z J Med       Date:  1989-02

5.  Features of endothelial dysfunction in early diabetic nephropathy.

Authors:  T Jensen; J Bjerre-Knudsen; B Feldt-Rasmussen; T Deckert
Journal:  Lancet       Date:  1989-03-04       Impact factor: 79.321

Review 6.  Albuminuria reflects widespread vascular damage. The Steno hypothesis.

Authors:  T Deckert; B Feldt-Rasmussen; K Borch-Johnsen; T Jensen; A Kofoed-Enevoldsen
Journal:  Diabetologia       Date:  1989-04       Impact factor: 10.122

7.  Predicting diabetic nephropathy in insulin-dependent patients.

Authors:  C E Mogensen; C K Christensen
Journal:  N Engl J Med       Date:  1984-07-12       Impact factor: 91.245

8.  Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.

Authors:  S L Jones; C F Close; M B Mattock; R J Jarrett; H Keen; G C Viberti
Journal:  BMJ       Date:  1989-02-25

9.  Blood rheology and cardiovascular risk factors in type 1 diabetes: relationship with microalbuminuria.

Authors:  R H Jay; S L Jones; C E Hill; W Richmond; G C Viberti; M W Rampling; D J Betteridge
Journal:  Diabet Med       Date:  1991 Aug-Sep       Impact factor: 4.359

10.  Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants.

Authors:  M Jauhiainen; P Koskinen; C Ehnholm; M H Frick; M Mänttäri; V Manninen; J K Huttunen
Journal:  Atherosclerosis       Date:  1991-07       Impact factor: 5.162

View more
  5 in total

Review 1.  Lipids and diabetic nephropathy.

Authors:  Rey F Rosario; Sharma Prabhakar
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 2.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

3.  Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM. Results from follow-up in the Diabetes Control and Complications Trial.

Authors:  J Q Purnell; S M Marcovina; J E Hokanson; H Kennedy; P A Cleary; M W Steffes; J D Brunzell
Journal:  Diabetes       Date:  1995-10       Impact factor: 9.461

4.  Antiproliferative effect of fluvastatin and thiazolidinedione in mesangial cells of diabetic rats.

Authors:  Mitsuru Okada; Hidehiko Yanagida; Hiroaki Kuwajima; Tsukasa Takemura
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

5.  Small dense low-density lipoprotein as a potential risk factor of nephropathy in type 2 diabetes mellitus.

Authors:  Essam Abd-Allha; Basma Badr Hassan; Mohamad Abduo; Seham Ahmed Omar; Hamdy Sliem
Journal:  Indian J Endocrinol Metab       Date:  2014-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.